Kyowa Kirin, Inc.
48
5
7
30
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
18.8%
9 terminated/withdrawn out of 48 trials
76.9%
-9.6% vs industry average
23%
11 trials in Phase 3/4
53%
16 of 30 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (48)
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Role: lead
Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
Role: collaborator
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
Role: collaborator
Effect of Istradefylline Treatment on Behavioral Measures of Apathy in Parkinson's Disease.
Role: collaborator
A Study of KK2269 in Adult Participants With Solid Tumors
Role: collaborator
A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia
Role: collaborator
Istradefylline for Parkinson Disease With Cognitive Impairment
Role: collaborator
Burden of Disease and Functional Impairment in XLH
Role: collaborator
Istradefylline Effect Protocol on Parkinson's Disease Tremor
Role: collaborator
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
Role: collaborator
Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer
Role: lead
Efficacy and Safety of Burosumab Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With XLH
Role: lead
Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab
Role: lead
Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
Role: lead
Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)
Role: lead
Study to Assess Bioequivalence and Adhesion Properties Between Two Granisetron Transdermal Patches.
Role: lead
An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia
Role: lead
An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001
Role: lead
Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)
Role: lead
Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)
Role: lead